Облигации: Insmed, 0.75% 1jun2028, USD (Conv.) (FIGI BBG010Z2B333, WKN A3KRDC)
Конвертируемые, Trace-eligible, Senior Unsecured
Конвертируемые, Trace-eligible, Senior Unsecured
|
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients ...
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders.
|
|
|
|
|
|
|
|
|
|
|
Откройте глобальную базу данных
1 000 000
облигаций
80 234
акций
168 394
ETF & Funds
80 000
индексов
Отслеживайте свой портфель наиболее эффективным способом
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |